211 
Market Cap
As of January 2, 2012: $32,213,000.00
Stock Chart
Avexa - 30 Day Poll
Recent BLOGS About Avexa Add New
 |
Avexa - buy or sell now that it has given up on it…
Given AVX is down almost 80% does anyone feel it should be a buy or sell now that it has given up on… Read more
|
Latest Company News
|
AVEXA LIMITED : Mr Handojo (Jet) Soedirdja resigns as a Non-Executive Director
4-traders (press release) - Feb 1, 2012 Company announcement Mr Handojo (Jet) Soedirdja resigns as a Non-Executive Director Melbourne, Australia. Tuesday 31 January 2012 The board of Avexa Limited [ASX:AVX] today announced that Mr Handojo (Jet) Soedirdja has resigned as a Non-Executive ...
|
|
AVEXA LIMITED : Avexa files to extend ATC patent life
4-traders (press release) - Jan 11, 2012 Melbourne, Australia - 23rd November 2011 - Melbourne-based biotechnology company Avexa Limited [ASX:AVX] today announced that it has filed two new patents covering the company's Apricitabine (ATC) program.
|
Website
Videos related to Avexa
Company Profile
Cash Assets: approx. $28M as of 30th Mar 2010. For 2008 & 2009 the company has had a loss of approxiamtely $18M each year.
Avexa is engaged in the development and commercialization of anti-infective pharmaceutical programs and projects. Avexa's principal research programs focus on the discovery of innovative medicines for the treatment of the diseases caused by:
- Human Immunodeficiency Virus (HIV)
- Vancomycin- and methicillin-resistant bacteria.
Avexa is engaged in the development and commercialization of anti-infective pharmaceutical programs and projects. Avexa's principal research programs focus on the discovery of innovative medicines for the treatment of the diseases caused by:
- Human Immunodeficiency Virus (HIV)
- Vancomycin- and methicillin-resistant bacteria.
Its lead program is apricitabine (ATC), which is in phase III trials. Apricitabine is nucleoside reverse transcriptase inhibitors (NRTI) for the treatment of human immunodeficiency virus (HIV) infection. The phase III study is conducted in 130 specialist HIV centers in 15 countries. This drug is targetd at 2nd, 3rd and 4th line therapy for cases of drug resiatnce to other treatment modalities.
The company’s other HIV focus, an integrase program, focuses to identify compounds, which inhibit HIV integrase, the enzyme for inserting the viral genome into the host cell deoxyribonucleic acid (DNA).
Its antibacterial program is focused on identifying compounds with antibacterial activity against antibiotic-resistant micro-organisms. A lead molecule, AVX13616, is selected for pre-clinical testing.
Possible Upcoming events:
Apricitabine (ATC) is in a phase III study.
Related companies or competition:
- Gilead Sciences
Terms & Rules
As per ASIC Regulatory Guide 162: All investment tips and comments appearing on this website (Poll results, BLOGS & discussion forums) are submitted by the general public who are not licensed financial advisors. None of the information on this website is financial or investment advice, you should seek independent financial or investment advice by a licensed financial or investment advisor before entering into any position of financial risk. Before using this website, you must agree to the BioInvesting.com.au Terms Of Use